Anebulo Pharmaceuticals remains a clinical-stage, pre-revenue biotechnology company focused on treatments for acute cannabinoid intoxication and substance addiction. In QQ4 2024, the company reported operating expenses of $1.34 million and a net loss of $1.35 million, with no revenue. The quarter generated a negative EBITDA of $1.29 million and a cash burn of approximately $2.05 million, leaving cash and cash equivalents of $3.09 million at quarter-end. While the balance sheet displays strong liquidity metrics (current ratio of 13.46 and a cash position that supports short-term liquidity), the company carries a sizable accumulated deficit (-$65.40 million) and depends on external funding to sustain operations absent revenue generation. The near-term outlook hinges on progression of ANEB001 and any forthcoming financing or partnering activity, as the company’s forward guidance, if any, is not provided in the supplied data.
Key Performance Indicators
Operating Income
Increasing
-1.34M
QoQ: 19.47% | YoY: 46.27%
Net Income
Increasing
-1.35M
QoQ: 18.38% | YoY: 45.91%
EPS
Increasing
-0.05
QoQ: 18.03% | YoY: 47.70%
Revenue Trend
Margin Analysis
Financial Highlights
Key quarterly metrics (Q4 2024):
- Revenue: none reported
- Operating income: -$1.34 million; YoY +46.27%, QoQ +19.47%
- Net income: -$1.35 million; YoY +45.91%, QoQ +18.38%
- EPS: -$0.0523; YoY +47.70%, QoQ +18.03%
- R&D expenses: $0.4677 million; G&A expenses: $0.8727 million
- EBITDA: -$1.29 million
- Net cash provided by operating activities: -$2.0529 million
- Free cash flow: -$2.0529 million
- Cash end of period: $3.0942 million; Beginning cash: $5.1471 million
- Total current assets: $3.50799 million; Total assets: $4.07311 million
- Total current liabilities: $0.26058 million; Total liabilities: $0.26058 million; Stockholders’ equity: $3.81253 million; Retained earnings: -$65.4037 million
- Current ratio: 13.46; Cash ratio: 11.87; Net income margin and other profitability metrics remain negative given the pre-revenue status
- Weighted average shares: 25.822 million
Income Statement
Metric
Value
YoY Change
QoQ Change
Operating Income
-1.34M
46.27%
19.47%
Net Income
-1.35M
45.91%
18.38%
EPS
-0.05
47.70%
18.03%
Key Financial Ratios
Return on Assets
Weak
-0.33%
Return on assets suggests inefficient capital allocation
Return on Equity
Weak
-0.35%
Return on equity suggests inefficient capital allocation
Current Ratio
Strong
13.46
Current ratio indicates excellent liquidity and financial flexibility
P/E Ratio
Negative
-12.82x
Negative earnings make P/E ratio not meaningful
Price to Book
High Premium
18.15x
Very high premium suggests asset-light business model or lofty expectations
Management Insights Available for Members
Get exclusive access to management commentary, earnings call quotes, and forward guidance from company leadership.